3 completed, 1 active not recruiting. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Active not recruiting 1 |
Follow AZD6234: new trials by email Literature Review of AZD6234 trials Research Report on AZD6234
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight AZD6234, Placebo, AZD9550 - Obesity/Overweight | Phase 2 | Active not recruiting | AstraZeneca | 16 | 2025-05-20 | 2026-09-29 |
| Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist AZD6234, Placebo to match - Endocrinology, Diabetes, Type II | Phase 2 | Completed | AstraZeneca | 69 | 2025-03-12 | 2026-09-24 |
| A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone AZD9550, AZD6234, Placebo comparator - Obesity or Overweight | Phase 2 | Completed | AstraZeneca | 377 | 2025-02-18 | 2026-06-03 |
| A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity AZD6234, Placebo comparator - Obesity or Overweight | Phase 2 | Completed | AstraZeneca | 262 | 2024-10-01 | 2026-10-02 |
Obesity (4) · Overweight (3) · Diabetes Mellitus, Type 2 (1)
AstraZeneca (4)
United States (3) · Australia (2) · Canada (2) · Japan (2) · China (1) · Germany (1) · United Kingdom (1)